Skip to main content
Signal8

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Brainstorm Cell Therapeutics Inc. logo

Brainstorm Cell Therapeutics Inc.

OTC:BCLIHealthcare
AH+0.00%$0.8810
Close$0.8810-7.26%
Mkt Cap$12.56M
EV-
Float11.42M
O/S14.26M
VOL83K sh
$ Vol$79K
RVOL3.75×
Inst Own-
SI0.5%
Net Cash/Sh-
Dilution
Brainstorm Cell Therapeutics Inc. logoOTC:BCLIAH$0.8810+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20260.96000.99800.88100.881082,506
Nov 16, 20260.95020.95020.89100.95006,364
Nov 13, 20260.99001.000.97000.990047,716
Nov 12, 20260.98991.020.95001.0053,284
Nov 11, 20260.99000.99000.87570.989815,040
Nov 10, 20260.96000.98500.88460.972927,312
Nov 9, 20260.87500.96000.83000.960033,558
Nov 6, 20260.93240.93240.80470.90005,418
Nov 5, 20260.82000.90050.70000.860021,972
Nov 4, 20260.82610.82610.81090.82615,699
Nov 3, 20260.82570.85000.82570.850012,206
Nov 2, 20260.82820.95700.82570.95705,422
Oct 30, 20260.87030.94300.85000.86016,560
Oct 29, 20260.79990.94310.79980.908778,591
Oct 28, 20260.75260.79980.75260.79984,721
Oct 27, 20260.80000.80000.75270.79992,566
Oct 26, 20260.78820.80310.76500.77226,538
Oct 23, 20260.79990.83360.75260.821928,861
Oct 22, 20260.75180.83490.75180.776011,513
Oct 21, 20260.75170.83440.75170.77003,196
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
3
HOLD
0
SELL
0
TOTAL3
Insider Trades
InsiderTypeShares
Pitts Peter Joe profile photoPitts Peter JoeGrant/Award900.0K
FRENKEL JACOB A profile photoFRENKEL JACOB AGrant/Award100.0K
Patlis Alla profile photoPatlis AllaGrant/Award100.0K
FRENKEL JACOB A profile photoFRENKEL JACOB AGrant/Award200.0K
Lebovits Chaim profile photoLebovits ChaimGrant/Award1.80M
Yablonka Uri profile photoYablonka UriGrant/Award150.0K
Shareholders
0.0%
Institutional
(0)
21.9%
Insiderⓘ
(11)
3.4%
5%+ Owners
(2)
of which 3.4% rests on schedules older than 24 months (2 holders)
74.8%
Unattributed (incl. retail)ⓘ
Insider21.9%
5%+ Beneficial3.4%
Unattributed (incl. retail)74.8%
Top Shareholders
NameShares%
Lebovits Chaim profile photo
Lebovits Chaim
President & CEO
2.0M14.0%
Armistice Capital, LLC logo
Armistice Capital, LLC
· filed May 2025
717.5K5.0%
FRENKEL JACOB A profile photo
FRENKEL JACOB A
Director
343.8K2.4%
Matthew J. Ruck logo
Matthew J. Ruck
· may incl. warrants· stale · filed Nov 2024
275.8K1.9%
Yablonka Uri profile photo
Yablonka Uri
EVP & Chief Business Officer, Director
218.5K1.5%
Kevin D. Ness logo
Kevin D. Ness
· may incl. warrants· stale · filed Feb 2024
204.0K1.4%
ARBEL IRIT profile photo
ARBEL IRIT
Director
161.1K1.1%
Patlis Alla profile photo
Patlis Alla
See Remarks
144.3K1.0%
Dagher Ibrahim B. profile photo
Dagher Ibrahim B.
Chief Medical Officer
66.8K0.5%
HARTOUNIAN HARTOUN profile photo
HARTOUNIAN HARTOUN
EVP, Chief Operating Officer
52.0K0.4%
Sources: Form 4, 13D/13GO/S: 14.3M · as of 11 Nov 2026 · SEC filings
Insiders & Institutional Holders

Insiders

About

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS).

Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004.

Its corporate headquarters are situated in New York, New York.

Key Metrics
Market Cap$12.56M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateOct 7, 2003
Shares Outstanding14.26M
Authorized Shares
Float11.42M
52-Week Range
$0.4589$1.69
$0.8810(34th percentile)
Volume
Average Daily Volume22.00K
82.51K today vs 22.00K avg(+275%)

30d Avg

22.00K

60d Avg

16.54K

90d Avg

18.56K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of BCLI as of Sep 30, 2026 records an effective S-3 shelf registration (effective Sep 27, 2024), an at-the-market sales agreement dated Aug 9, 2021, 7 outstanding warrant series and a PIPE closed Oct 27, 2026, from SEC filings. Brainstorm Cell Therapeutics Inc. (OTC: BCLI) traded at $0.8810 on Nov 17, 2026, down 7.26% from the previous close of $0.9500. 52-week range: $0.4589 to $1.69. The company is in the Healthcare sector (Biotechnology).